Evidence Table 90. KQ2—Continuous data—Ejection fraction

| **Author Year**  **Study Design** | **CHD Risk Category** | **CVD drug** | **Dose** | **Supplement/. Control** | **N** | **Definition of outcome** | **Post treatment Mean/**  **(Median)**  **SD/SE**  **Lower limit (IQR, 95% CI)**  **Upper Limit (IQR, 95% CI)** | **Mean change/% change from baseline/**  **SD/**  **P Value** | **Between group differences in Means/ medians**  **SD/**  **P Value** | **Summary of Results** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 36585 | At high risk for CHD | ACE inhibitors (no description); furosemide; digoxin, also hydralazine and/or nitrates | NR | Coenzyme Q10 | 27 | at 12 wks of treatment | Mean: 31  Median  SD: 9  SE:  Lower:  Upper: | Mean:5  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: |  | medium |
|  | Placebo | 27 | Mean:31  Median  SD: 9  SE:  Lower:  Upper: | Mean:5  Median:  SD:  P: |